Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
2 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ascentage Pharma Group International American Depository Shares’s names, not what it holds today.
Patents granted
2
2 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 2 in 2024 and none in 2023
Applications published
11
3 of them in 2025
Names they are printed under
3
a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
GUANGZHOU HEALTHQUEST PHARMA CO., LTD. a subsidiary
named as the applicant on its applications, in CN
0 granted
9 publishedGUANGZHOU HEALTHQUEST PHARMA CO., LTD. a subsidiary
CN, as the owner printed on each patent
2 granted
0 publishedSHANGHAI YASHENG PHARMACEUTICAL TECHNOLOGY CO., LTD. a subsidiary
named as the applicant on its applications, in CN
0 granted
2 published
Names not counted (2)
Ascentage Pharma Group Corp Limited
Most of its patents print CN; this name counts in HK, US. 0 granted and 62 published under it are not counted.
Ascentage Pharma Group Corp Limited
Most of its patents print CN; this name counts in HK, US. 21 granted and 3 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 24, 2025 | 2025/0235426 | Pharmaceutical Combination and Use Thereof | Pharmaceuticals | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. |
| May 29, 2025 | 2025/0170125 | NOVEL APPLICATION OF GZD824 AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN TREATING DISEASES | Pharmaceuticals | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. |
| Feb 20, 2025 | 2025/0057834 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYNYL COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | Pharmaceuticals | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. |
| Jul 18, 2024 | 2024/0238251 | A Composition Comprising Heterocyclic Compounds, Preparation Method and Application Thereof | Pharmaceuticals | SHANGHAI YASHENG PHARMACEUTICAL TECHNOLOGY CO., LTD. |
| Dec 21, 2023 | 2023/0404998 | Combination Therapies for Treating Cancer | Pharmaceuticals | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. |
| Dec 7, 2023 | 2023/0390245 | A Composition Comprising Heterocyclic Compounds, Preparation Method and Application Thereof | Pharmaceuticals | SHANGHAI YASHENG PHARMACEUTICAL TECHNOLOGY CO., LTD. |
| Mar 16, 2023 | 2023/0078120 | Methods for Treating Coronavirus Infections | Pharmaceuticals | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. |
| Sep 22, 2022 | 2022/0296587 | Pharmaceutical composition containing alkynyl compound and preparation method and application thereof | Pharmaceuticals | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. · patent 12,097,195 granted from it |
| Jun 23, 2022 | 2022/0193071 | METHODS FOR CANCER THERAPY | Pharmaceuticals | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. |
| May 12, 2022 | 2022/0142975 | Pharmaceutical Combination and Use Thereof | Pharmaceuticals | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. · patent 12,233,047 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 4.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.